(Q39523597)

12 September 2017

title

Towards microRNA-based therapeutics for diabetic nephropathy (English)

1 reference

12 September 2017

1 reference

M L Alvarez

1

1 reference

12 September 2017

J K DiStefano

series ordinal

2

1 reference

12 September 2017

publication date

8 November 2012

1 reference

12 September 2017

1 reference

12 September 2017

volume

56

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

444-456

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-012-2768-x

12 September 2017

exact match

0 references

cites work

Diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Towards understanding the inherited susceptibility for nephropathy in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

A glimpse of various pathogenetic mechanisms of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-directed transcriptional gene silencing in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Gene silencing by microRNAs: contributions of translational repression and mRNA decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Role of microRNAs in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNAs and the glomerulus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The Drosha-DGCR8 complex in primary microRNA processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA genes are transcribed by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Most mammalian mRNAs are conserved targets of microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

GLUT1 and TGF-beta: the link between hyperglycaemia and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Toward microRNA-based therapeutics for heart disease: the sense in antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Inhibition of microRNA function by antimiR oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA sponges: progress and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Analysis of microRNA knockouts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNAs in renal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The pro-apoptotic protein Bim is a microRNA target in kidney progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The microRNA-processing enzyme dicer maintains juxtaglomerular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

A pancreatic islet-specific microRNA regulates insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

miR-375 maintains normal pancreatic alpha- and beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

21 January 2018

MicroRNA therapeutics.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Prediction of mammalian microRNA targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-133 controls cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Inhibition of microRNA with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Sequence-specific inhibition of small RNA function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Improved targeting of miRNA with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

LNA-modified oligonucleotides mediate specific inhibition of microRNA function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Double-stranded regions are essential design components of potent inhibitors of RISC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Silencing of microRNAs in vivo with 'antagomirs'

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

LNA-mediated microRNA silencing in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Potent inhibition of microRNA in vivo without degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Developing microRNA therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

siRNAs can function as miRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Riboregulators in kidney development and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Exploring RNA interference as a therapeutic strategy for renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Therapeutic potential for microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Construction of an artificial MicroRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The promise of microRNA replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

In vivo delivery of cytoplasmic RNA virus-derived miRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Identification of a microRNA signature in renal fibrosis: role of miR-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Specificity, duplex degradation and subcellular localization of antagomirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Silencing of microRNA families by seed-targeting tiny LNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2768-X

Lentiviral vector-mediated expression of pre-miRNAs and antagomiRs

21 January 2018

1 reference

12 December 2020

Dicer cuts the kidney

1 reference

12 December 2020

Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells

1 reference

12 December 2020

The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience

1 reference

12 December 2020

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

1 reference

12 December 2020

Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1007/S00125-012-2768-X

Identifiers

DOI

1 reference

12 September 2017

1 reference